Analystreport

Reata Pharmaceuticals Inc (NASDAQ: RETA) had its price target lowered by analysts at Robert W. Baird from $283.00 to $268.00. They now have an "outperform" rating on the stock.

Reata Pharmaceuticals, Inc. - Class A  (RETA) 
Last reata pharmaceuticals, inc. - class a earnings: 2/19 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.reatapharma.com